Obesity is a chronic metabolic and genetic disease involving accumulation of excessive or abnormal fat in the body. Obesity surgeries decrease the size of the stomach, in order to limit the amount of food it can hold. This limits the quantity of food patients can ingest, leading to drastic weight loss. It has a beneficial effect on many medical conditions such as acid reflux, low back pain, diabetes, sleep apnea, hypertension, acid reflux, polycystic ovary syndrome (PCOS) and urinary stress incontinence. Increasing prevalence of obesity among children and adults is posing a threat in both developed and developing nations. Obesity has a major impact on population longevity and health-related expenses. Obesity surgeries result in 40% to 80% loss of excess weight after two to three years, depending on the obesity surgery procedure.
North America is facing serious public health issues due to rising obesity in the country. The U.S. accounted for 13% of obese persons worldwide in 2013. Obesity is a major public health challenge in Europe. Approximately, 52% of the population in the European Union was obese or overweight in 2010. Obesity has reached epidemic proportions in many countries in Asia Pacific. South East Asia and Western Pacific regions are facing an epidemic of obesity-associated diseases such as cardiovascular disorders and diabetes. Some of the leading factors leading to obesity in the region are sedentary lifestyle, lack of awareness and cultural attitude.
Increasing obesity epidemic and change in lifestyle are driving growth for obesity surgery devices market. Changes in nature of work, leisure time activities and food habits are the most significant contributing factors to the drastic increase of obesity in the world. In addition, increased medical tourism promotes obesity surgeries, as price is considered to be an important factor when it comes to obesity surgery. However, the selective nature of the surgery, long-term and short-term complications undergoing surgeries and limited insurance coverage restricts growth for the obesity surgery devices market. Obesity surgery is also not recommended for anyone suffering from serious illnesses such as cancer, liver diseases, cardiac, pulmonary and renal insufficiency. In addition, inadequate insurance coverage for the procedure and excessive cost of surgery often makes it unaffordable.
This report provides in-depth analysis and estimation of the obesity surgery devices market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics including market drivers, restraints, trends and strategic developments has been provided in the report. The obesity surgery devices market is categorized on the basis of procedure for obesity surgery, devices and geography. Based on procedure of obesity surgery, the obesity surgery devices market comprises adjustable gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch. Based on devices, the market comprises staples, intragastric balloons, gastric bands and gastric electrical stimulation.
In the geographical analysis, the report identifies and analyses market size and forecast of North America, Europe, Asia and Rest of the World (Row). Some of the major players in the obesity surgery devices market are Johnson & Johnson, Medtronic, Inc., Apollo Endosurgery Inc, Aspire Bariatrics, Spatz FGIA Inc., MetaCure and IntraPace Inc. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote